D
Blueprint Medicines Corporation
BPMC
$89.25
$3.313.85%
D
Sell
10/31/2023Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 10/31/2023 due to an increase in the volatility index.
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 10/31/2023 due to an increase in the volatility index.
E
Sell
9/25/2023Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D- on 9/25/2023 due to a decline in the total return index and volatility index.
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D- on 9/25/2023 due to a decline in the total return index and volatility index.
D
Sell
9/8/2023Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 9/8/2023 due to an increase in the total return index and volatility index.
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 9/8/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.23 to 0.29, and the quick ratio declined from 6.6 to 5.36.
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.23 to 0.29, and the quick ratio declined from 6.6 to 5.36.
D
Sell
2/9/2023Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
Blueprint Medicines Corporation (BPMC) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
Blueprint Medicines Corporation (BPMC) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/2/2022Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 11/2/2022 due to an increase in the growth index. Total revenue increased 80.53% from $36.55M to $65.98M, EBIT increased 21.16% from -$157.64M to -$124.28M, and earnings per share increased from -$2.6789 to -$2.23.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 11/2/2022 due to an increase in the growth index. Total revenue increased 80.53% from $36.55M to $65.98M, EBIT increased 21.16% from -$157.64M to -$124.28M, and earnings per share increased from -$2.6789 to -$2.23.
D
Sell
3/7/2022Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 3/7/2022 due to a substantial decline in the total return index, efficiency index and volatility index. Net income declined 171.82% from -$117.24M to -$318.69M, and total capital declined 18.69% from $1.33B to $1.08B.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 3/7/2022 due to a substantial decline in the total return index, efficiency index and volatility index. Net income declined 171.82% from -$117.24M to -$318.69M, and total capital declined 18.69% from $1.33B to $1.08B.
D
Sell
12/6/2021Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D from D+ on 12/6/2021 due to a decline in the total return index.
Blueprint Medicines Corporation (BPMC) was downgraded to D from D+ on 12/6/2021 due to a decline in the total return index.
D
Sell
11/18/2021Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D+ from D on 11/18/2021 due to an increase in the total return index and volatility index.
Blueprint Medicines Corporation (BPMC) was upgraded to D+ from D on 11/18/2021 due to an increase in the total return index and volatility index.
D
Sell
11/3/2021Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D from C- on 11/3/2021 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 51.34% from -$63.17M to -$95.6M, total revenue declined 11.38% from $27.3M to $24.19M, and net income declined 8.11% from -$108.44M to -$117.24M.
Blueprint Medicines Corporation (BPMC) was downgraded to D from C- on 11/3/2021 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 51.34% from -$63.17M to -$95.6M, total revenue declined 11.38% from $27.3M to $24.19M, and net income declined 8.11% from -$108.44M to -$117.24M.
C
Hold
5/3/2021Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to C- from D+ on 5/3/2021 due to a major increase in the growth index, valuation index and efficiency index.
Blueprint Medicines Corporation (BPMC) was upgraded to C- from D+ on 5/3/2021 due to a major increase in the growth index, valuation index and efficiency index.
D
Sell
2/23/2021Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D+ from C- on 2/23/2021 due to a decline in the total return index.
Blueprint Medicines Corporation (BPMC) was downgraded to D+ from C- on 2/23/2021 due to a decline in the total return index.
C
Hold
2/19/2021Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to C- from C on 2/19/2021 due to a significant decline in the growth index, efficiency index and volatility index. Earnings per share declined from $11.16 to -$1.5278, EBIT declined 113.57% from $633.37M to -$85.97M, and net income declined 113.51% from $633.98M to -$85.67M.
Blueprint Medicines Corporation (BPMC) was downgraded to C- from C on 2/19/2021 due to a significant decline in the growth index, efficiency index and volatility index. Earnings per share declined from $11.16 to -$1.5278, EBIT declined 113.57% from $633.37M to -$85.97M, and net income declined 113.51% from $633.98M to -$85.67M.
C
Hold
11/3/2020Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to C from D on 11/3/2020 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 8,831.06% from $8.34M to $745.12M, operating cash flow increased 715.17% from -$101.16M to $622.33M, and net income increased 613.45% from -$123.47M to $633.98M.
Blueprint Medicines Corporation (BPMC) was upgraded to C from D on 11/3/2020 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 8,831.06% from $8.34M to $745.12M, operating cash flow increased 715.17% from -$101.16M to $622.33M, and net income increased 613.45% from -$123.47M to $633.98M.
D
Sell
5/1/2020Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 5/1/2020 due to a major increase in the growth index. Total revenue increased 463.88% from $9.14M to $51.53M, operating cash flow increased 37.39% from -$71.7M to -$44.9M, and earnings per share increased from -$1.9271 to -$1.3477.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 5/1/2020 due to a major increase in the growth index. Total revenue increased 463.88% from $9.14M to $51.53M, operating cash flow increased 37.39% from -$71.7M to -$44.9M, and earnings per share increased from -$1.9271 to -$1.3477.
D
Sell
11/7/2019Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 11/7/2019 due to a significant decline in the total return index, solvency index and efficiency index. The quick ratio declined from 7.34 to 5.3, and total capital declined 11.27% from $691.83M to $613.85M.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 11/7/2019 due to a significant decline in the total return index, solvency index and efficiency index. The quick ratio declined from 7.34 to 5.3, and total capital declined 11.27% from $691.83M to $613.85M.
D
Sell
8/2/2019Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 8/2/2019 due to a significant increase in the total return index, solvency index and efficiency index. Total capital increased 55.88% from $443.81M to $691.83M, debt to equity declined from 0.02 to 0.01, and the quick ratio increased from 6.42 to 7.34.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 8/2/2019 due to a significant increase in the total return index, solvency index and efficiency index. Total capital increased 55.88% from $443.81M to $691.83M, debt to equity declined from 0.02 to 0.01, and the quick ratio increased from 6.42 to 7.34.
D
Sell
5/15/2019Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index, growth index and efficiency index. Total revenue declined 29.33% from $1.03M to $730, the quick ratio declined from 8.19 to 6.42, and operating cash flow declined 18.65% from -$67.58M to -$80.19M.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index, growth index and efficiency index. Total revenue declined 29.33% from $1.03M to $730, the quick ratio declined from 8.19 to 6.42, and operating cash flow declined 18.65% from -$67.58M to -$80.19M.
D
Sell
3/29/2019Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 3/29/2019 due to an increase in the volatility index and total return index.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 3/29/2019 due to an increase in the volatility index and total return index.
D
Sell
3/4/2019Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 3/4/2019 due to a major decline in the total return index, efficiency index and volatility index. Total capital declined 14.41% from $489.57M to $419.01M, and net income declined 10.45% from -$72.72M to -$80.32M.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 3/4/2019 due to a major decline in the total return index, efficiency index and volatility index. Total capital declined 14.41% from $489.57M to $419.01M, and net income declined 10.45% from -$72.72M to -$80.32M.
D
Sell
5/7/2018Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D from D+ on 5/7/2018 due to a noticeable decline in the total return index, growth index and efficiency index. Operating cash flow declined 42.63% from -$34.75M to -$49.56M, total revenue declined 41.4% from $1.63M to $954, and EBIT declined 17.6% from -$50.09M to -$58.91M.
Blueprint Medicines Corporation (BPMC) was downgraded to D from D+ on 5/7/2018 due to a noticeable decline in the total return index, growth index and efficiency index. Operating cash flow declined 42.63% from -$34.75M to -$49.56M, total revenue declined 41.4% from $1.63M to $954, and EBIT declined 17.6% from -$50.09M to -$58.91M.
D
Sell
2/23/2018Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D+ from D on 2/23/2018 due to an increase in the efficiency index, volatility index and growth index. Total capital increased 82.18% from $343.34M to $625.49M.
Blueprint Medicines Corporation (BPMC) was upgraded to D+ from D on 2/23/2018 due to an increase in the efficiency index, volatility index and growth index. Total capital increased 82.18% from $343.34M to $625.49M.
D
Sell
8/4/2017Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 8/4/2017 due to a noticeable increase in the total return index, efficiency index and solvency index. Total capital increased 96.77% from $191.47M to $376.76M, the quick ratio increased from 8.12 to 12.85, and debt to equity declined from 0.02 to 0.01.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 8/4/2017 due to a noticeable increase in the total return index, efficiency index and solvency index. Total capital increased 96.77% from $191.47M to $376.76M, the quick ratio increased from 8.12 to 12.85, and debt to equity declined from 0.02 to 0.01.
D
Sell
5/10/2017Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/10/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Operating cash flow declined 65.35% from -$18.8M to -$31.08M, EBIT declined 32.55% from -$21.37M to -$28.33M, and net income declined 31.58% from -$21.26M to -$27.98M.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/10/2017 due to a noticeable decline in the growth index, solvency index and efficiency index. Operating cash flow declined 65.35% from -$18.8M to -$31.08M, EBIT declined 32.55% from -$21.37M to -$28.33M, and net income declined 31.58% from -$21.26M to -$27.98M.
D
Sell
3/10/2017Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 3/10/2017 due to a significant increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.05 to 0.02, and the quick ratio increased from 6.4 to 7.64.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 3/10/2017 due to a significant increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.05 to 0.02, and the quick ratio increased from 6.4 to 7.64.
D
Sell
5/13/2016Downgrade
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/13/2016 due to a noticeable decline in the solvency index, growth index and efficiency index. Total capital declined 10.01% from $151.32M to $136.18M, the quick ratio declined from 8.91 to 8.23, and EBIT declined 0.03% from -$15.42M to -$15.43M.
Blueprint Medicines Corporation (BPMC) was downgraded to D- from D on 5/13/2016 due to a noticeable decline in the solvency index, growth index and efficiency index. Total capital declined 10.01% from $151.32M to $136.18M, the quick ratio declined from 8.91 to 8.23, and EBIT declined 0.03% from -$15.42M to -$15.43M.
D
Sell
5/3/2016Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 5/3/2016 due to an increase in the valuation index and efficiency index.
Blueprint Medicines Corporation (BPMC) was upgraded to D from D- on 5/3/2016 due to an increase in the valuation index and efficiency index.
D
Sell
1/4/2016Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 1/4/2016 due to an increase in the growth index. Total revenue increased 27.5% from $2.69M to $3.43M, operating cash flow increased 12.75% from -$11.06M to -$12.47M, and EBIT increased 0.65% from -$12.4M to -$12.48M.
Blueprint Medicines Corporation (BPMC) was upgraded to D- from E+ on 1/4/2016 due to an increase in the growth index. Total revenue increased 27.5% from $2.69M to $3.43M, operating cash flow increased 12.75% from -$11.06M to -$12.47M, and EBIT increased 0.65% from -$12.4M to -$12.48M.
E
Sell
10/1/2015Upgraded
Blueprint Medicines Corporation (BPMC) was upgraded to E+ from E on 10/1/2015 due to a large increase in the solvency index and valuation index.
Blueprint Medicines Corporation (BPMC) was upgraded to E+ from E on 10/1/2015 due to a large increase in the solvency index and valuation index.
E
Sell
8/12/2015None
Blueprint Medicines Corporation (BPMC) was downgraded to E from U on 08/12/2015.
Blueprint Medicines Corporation (BPMC) was downgraded to E from U on 08/12/2015.
NASDAQ
04/02/2025 12:49PM Eastern
Quotes delayed
